Page 88 - 《中国药房》2024年23期

[13] HIGGINS J P，ALTMAN D G，GøTZSCHE P C，et al. ment in type 1 diabetes：the ADJUNCT ONE treat-to-
The Cochrane Collaboration’s tool for assessing risk of target randomized trial[J]. Diabetes Care，2016，39（10）：
bias in randomised trials [J]. BMJ，2011，343：d5928. 1702-1710.
[14] AHRÉN B，HIRSCH I B，PIEBER T R，et al. Efficacy and [23] PIEBER T R，DELLER S，KORSATKO S，et al. Counter-
safety of liraglutide added to capped insulin treatment in regulatory hormone responses to hypoglycaemia in people
subjects with type 1 diabetes：the ADJUNCT TWO ran‐ with type 1 diabetes after 4 weeks of treatment with lira‐
domized trial[J]. Diabetes Care，2016，39（10）：1693-1701. glutide adjunct to insulin：a randomized，placebo-
[15] BALLAV C，DHERE A，KENNEDY I，et al. Lixisenatide controlled，double-blind，crossover trial[J]. Diabetes Obes
in type 1 diabetes：a randomised control trial of the effect Metab，2015，17（8）：742-750.
of lixisenatide on post-meal glucose excursions and gluca‐ [24] VON HERRATH M，BAIN S C，BODE B，et al. Anti-
gon in type 1 diabetes patients[J]. Endocrinol Diabetes interleukin-21 antibody and liraglutide for the preserva‐
Metab，2020，3（3）：e00130. tion of β-cell function in adults with recent-onset type 1
[16] DEJGAARD T F，FRANDSEN C S，HANSEN T S，et al. diabetes：a randomised，double-blind，placebo-controlled，
Efficacy and safety of liraglutide for overweight adult pa‐ phase 2 trial[J]. Lancet Diabetes Endocrinol，2021，9（4）：
tients with type 1 diabetes and insufficient glycaemic con‐ 212-224.
trol （Lira-1） ：a randomised，double-blind，placebo- [25] LIU L L，SHAO Z，XIA Y，et al. Incretin-based therapies
controlled trial[J]. Lancet Diabetes Endocrinol，2016，4 for patients with type 1 diabetes：a meta-analysis[J]. En‐
（3）：221-232. docr Connect，2019，8（3）：277-288.
[17] DEJGAARD T F，SCHMIDT S，FRANDSEN C S，et al. [26] FRANDSEN C S，DEJGAARD T F，ANDERSEN H U，
Liraglutide reduces hyperglycaemia and body weight in et al. Liraglutide as adjunct to insulin treatment in type 1
overweight，dysregulated insulin-pump-treated patients diabetes does not interfere with glycaemic recovery or ga-
with type 1 diabetes：the Lira Pump trial：a randomized， stric emptying rate during hypoglycaemia：a randomized，
double-blinded，placebo-controlled trial[J]. Diabetes Obes placebo-controlled，double-blind，parallel-group study[J].
Metab，2020，22（4）：492-500. Diabetes Obes Metab，2017，19（6）：773-782.
[18] DUBÉ M C，D’AMOURS M，WEISNAGEL S J. Beyond [27] GILON P. The role of α-cells in islet function and glucose
glycaemic control：a cross-over，double-blinded，24-week homeostasis in health and type 2 diabetes[J]. J Mol Biol，
intervention with liraglutide in type 1 diabetes[J]. Diabe‐ 2020，432（5）：1367-1394.
tes Obes Metab，2018，20（1）：178-184. [28] HUISING M O，VAN DER MEULEN T，HUANG J L，
[19] FRANDSEN C S，DEJGAARD T F，HOLST J J，et al. et al. The difference δ -cells make in glucose control[J].
Twelve-week treatment with liraglutide as add-on to insu‐ Physiology，2018，33（6）：403-411.
lin in normal-weight patients with poorly controlled type [29] RORSMAN P，HUISING M O. The somatostatin-
1 diabetes：a randomized，placebo-controlled，double- secreting pancreatic δ-cell in health and disease[J]. Nat
blind parallel study[J]. Diabetes Care，2015，38（12）： Rev Endocrinol，2018，14（7）：404-414.
2250-2257. [30] ORCI L，BAETENS D，RUFENER C，et al. Hypertrophy
[20] JOHANSEN N J，DEJGAARD T F，LUND A，et al. Effi‐ and hyperplasia of somatostatin-containing D-cells in dia‐
cacy and safety of meal-time administration of short- betes[J]. Proc Natl Acad Sci U S A，1976，73（4）：1338-
acting exenatide for glycaemic control in type 1 diabetes 1342.
（MAG1C） ： a randomised， double-blind， placebo- [31] GÓMEZ DUMM C L，CÓNSOLE G M，LUNA G C，
controlled trial[J]. Lancet Diabetes Endocrinol，2020，8 et al. Quantitative immunohistochemical changes in the
（4）：313-324. endocrine pancreas of nonobese diabetic （NOD） mice[J].
[21] KUHADIYA N D，DHINDSA S，GHANIM H，et al. Addi‐ Pancreas，1995，11（4）：396-401.
tion of liraglutide to insulin in patients with type 1 diabe‐ [32] NOVIKOVA L，SMIRNOVA I V，RAWAL S，et al. Varia‐
tes：a randomized placebo-controlled clinical trial of 12 tions in rodent models of type 1 diabetes：islet morphology
weeks[J]. Diabetes Care，2016，39（6）：1027-1035. [J]. J Diabetes Res，2013，2013：965832.
[22] MATHIEU C，ZINMAN B，HEMMINGSSON J U，et al. （收稿日期：2024-04-22 修回日期：2024-09-07）
Efficacy and safety of liraglutide added to insulin treat‐ （编辑：刘明伟）

· 2914 · China Pharmacy 2024 Vol. 35 No. 23 中国药房 2024年第35卷第23期